2024
Baseline Characteristics from Evoke and Evoke+: Two Phase 3 Randomized Placebo-controlled Trials of Oral Semaglutide in Patients with Early Alzheimer’s Disease (P11-9.013)
Scheltens P, Atri A, Feldman H, Hansson O, Knop F, Sano M, Dethlefsen C, Johannsen P, León T, Hansen C, Cummings J. Baseline Characteristics from Evoke and Evoke+: Two Phase 3 Randomized Placebo-controlled Trials of Oral Semaglutide in Patients with Early Alzheimer’s Disease (P11-9.013). Neurology 2024, 102 DOI: 10.1212/wnl.0000000000205079.Peer-Reviewed Original Research
2016
Role of INPP5D, PTK2B, ZCWPW1 and TREM 2 in Predicting Risk of Progression in Cognitively Impaired Subjects to Alzheimer's Disease (P5.166)
Hawkins C, Fok A, Feldman H, Sadovnick D, Hsiung G. Role of INPP5D, PTK2B, ZCWPW1 and TREM 2 in Predicting Risk of Progression in Cognitively Impaired Subjects to Alzheimer's Disease (P5.166). Neurology 2016, 86 DOI: 10.1212/wnl.86.16_supplement.p5.166.Peer-Reviewed Original Research